CDTX vs DASH
Cidara Therapeutics Inc (CDTX) versus DoorDash, Inc. Class A Common Stock (DASH) — a side-by-side from cached financials, not a winner call.
Cidara Therapeutics Inc (CDTX) is a biotechnology company listed on US.
DoorDash, Inc. Class A Common Stock (DASH) is a internet retail company listed on US.
Latest reported CDTX revenue for 2024-12-31 was $1.3M. Net income was -$169.8M. Revenue was down 94.5% from 2023-12-31 to 2024-12-31. CDTX currently screens at market cap $6.96B.
Latest reported DASH revenue for 2025-12-31 was $13.72B. Net income was $935.0M. Revenue was up 27.9% from 2024-12-31 to 2025-12-31. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
CDTX currently screens at market cap $6.96B. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
Not investment advice. Open the CDTX and DASH stock pages for the full models.
Not investment advice.